Inhibition of retinal angiogenesis by peptides derived from thrombospondin-1

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 8, 2000, Pages 2378-2388

  Shafiee, Afshin ^a,b   Penn, John S ^c   Krutzsch, Henry C ^d   Inman, John K ^d   Roberts, David D ^d   Blake, Diane A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; HEPARIN; PROCOLLAGEN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; CATTLE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; THROMBOSPONDIN 1; TIME FACTORS;

EID: 0033924566     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. American Academy of Ophthalmology. Eye Care for the American People. San Francisco: American Academy of Ophthalmology, 1987.
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
3. Forrester JV, Shafiee A, Schroder S, Knott R, McIntosh LC. The role of growth factors in proliferative diabetic retinopathy. Eye. 1993; 7:276-287.
4. Tolentino MJ, Adamis MP. Angiogenic factors in the development of diabetic iris ncovascularization and retinopathy. Int Ophthalmol Clin. 1998;38:77-94.
5. Robinson GS, Aiello LP. Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin. 1998;38:89-102.
6. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
7. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Nat Acad Sci USA. 1995;92:10457-10461.
8. Robinson GS, Pierce EA, Rook SL, Foley ED, Webb R, Smith LC. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Nat Acad Sci USA. 1996;93:4851-4856.
9. Grant SW, Kyshtobayeva AS, Kurosaki T, Jakowatz J, Fruchauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev. 1998;22:185-194.
10. Castle VP, Dixit VM, Polverini PJ. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum-and anchorage-independent NIH 3T3 cells. Lab Invest. 1997;77:51-61.
11. Sheibani N, Newman PJ, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, regulates platelet-endothelial cell adhesion molecule-1 expression and endothelial cell morphogenesis. Mol Biol Cell. 1997;8:1329-1341.
12. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-6511.
13. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol. 1994;124:183-193.
14. BenEzra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci. 1993,34:3601-3608.
15. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 1996;10:1183-1191.
16. Tolmsa SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin have anti-angiogenic activity. J Cell Biol. 1993;122:497-511.
17. Schultz-Cherry S, Chen H, Mosher DF, et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem. 1995;270:7304-7310.
18. Taraboletti G, Roberts DD, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility and growth: a potential angiogenesis regulatory factor. J Cell Biol. 1990;111:765-772.
19. Vogel T, Guo NH, Krutzsch HC, et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem. 1993;53:74-84
20. Guo NH, Krutzsch HC, Negre E, Zabrenctzky VS, Roberts DD. Heparin-binding peptides from the type I repeats of thrombospondin: structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J Biol Chem. 1992;267:19349-19335.
21. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol. 1997;138:707-717.
22. Chung J, Gao AG, Frazier WA. Thrombospondin acts via integrin-associated protein to activate the platelet integrin alpha IIb beta 3. J Biol Chem. 1997;272:14740-14746.
23. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 1998;92:391-400.
24. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Nat Acad Sci USA. 1996;93:9764-9769.
25. Guo NH, Krutzsch HC, Negre E, Vogel T, Blake DA, Roberts DD. Heparin-and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. Proc Nat Acad Sci USA. 1992;89:3040-3044.
26. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997;57:1735-1742.
27. Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD. Anti-proliferative and antitumor activities of D-reverse peptides derived from the second type-I repeat of thrombospondin-1. J Peptide Res. 1997;50:210-221.
28. Forrester JV, Chapman A, Kerr C, Roberts J, Lee WR, Lackie JM. Bovine retinal explants cultured in collagen gels: a model system for the study of proliferative retinopathy. Arch Ophthalmol. 1990; 108:415-420.
29. Sheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. Boca Raton, FL: CRC Press; 1996:397-405.
30. 2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995 36:2063-2070.
31. Penn JS, Henry MM. Assessing retinal neovascularization in an animal model of proliferative retinopathy. Microvasc Res. 1996; 51:126-130.
32. Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 198;39:840-845.
33. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors. 1998;16:1-9.
34. Flower RW, McLeod DS, Lutty GA, Goldberg B, Wajer SD. Postnatal retinal vascular development of the puppy. Invest Ophthalmol Vis Sci. 1985;26:957-968.
35. Holmes JM, Duffner A. The effect of growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res. 1996;15:403-409.
36. Zhang S, Leske DA, Uhl JR, Cockerill FR, Lanier WL, Holmes JM. Retinopathy associated with Enterococcus enteropathy in the neonatal rat. Invest Ophthalmol Vis Sci. 1999;40:1305-1309.
37. Holmes JM, Zhang S, Leske DA, Lanier WL. Metabolic acidosisinduced retinopathy in the neonatal rat. Invest Ophthalmol Vis Sci. 1999;40:804-809.
38. Holmes JM, Zhang S, Leske DA, Lanier WL. The effect of carbon dioxide on oxygen-induced retinopathy in the neonatal rat. Curr Eye Res. 1997;16:725-732.
39. Holmes JM, Zhang S, Leske DA, Lanier WL. Carbon dioxide-induced retinopathy in the neonatal rat. Curr Eye Res. 1998;17:608-616.
40. Zhang S, Leske DA, Holmes JM. Comparison of neovascularization grading methods in a rat model of retinopathy of prematurity [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1999;40(4):S700. Abstract nr 3695.
41. Penn J, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36:724-731.
42. Niesman MR, Johnson KA, Penn JS. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem Res. 1997;22:597-605.
43. Hugo C, Pichler RP, Schultze-Lohoff E, et al. Thrombospondin-peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo in experimental mesangial proliferative glomerulonephritis in the rat. Kidney Int. 1999;55:2236-2249.
44. Sheibani N, Frazier WA. Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. Mol Biol Cell. 1998;9:701-713.
45. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58: 1298-1304.
46. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Nat Acad Sci USA. 1995;92: 6788-6792.
47. Hsu SC, Volpert OV, Steck PA, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 1996;56:5684-5691.
48. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996;18:71-76.
49. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998; 93:1159-1170.
50. Baird A, Durkin T. Inhibition of endothelial cell proliferation by type beta-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun. 1986;138:476-482.
51. Iruela-Arispe ML, Sage EH. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-beta 1. J Cell Biochem. 1993;52:414-430.
52. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Nat Acad Sci USA. 1986;83:4167-4171.
53. Karnofsky MA, Badwey JA. Respiratory burst during phagocytosis: An overview. Methods Enzymol. 1986;132:353-354.
54. Muller-Kliesser WF, Sutherland RM. Influence of convection in the growth medium on oxygen tensions in multicellular spheroids. Cancer Res. 1982;42:237-242.
55. Lam K, Rao VS, Qasba PK. Molecular modeling studies on binding of bFGF to heparin and its receptor FGFR1. J Biomol Struct Dyn. 1998;15:1009-1027.
56. Colin S, Jeanny JC, Mascarelli F, et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol. 1999;55:74-82.
57. Sperinde GV, Nugent MA. Heparan sulfate proteoglycans control intracellular processing of bFGF in vascular smooth muscle cells. Biochemistry. 1998;37:13153-13164.
58. Doughtier AM, Wasserstrom H, Torley L, et al. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors. 1997;14:257-268.
59. Faham S, Hileman RE, Fromm JR, et al. Heparin structure and interactions with basic fibroblast growth factor. Science. 1996;271: 1116-1120.
60. Waksman G, Herr AB. New insights into heparin-induced FGF oligomerization. Nat Struct Biol. 1998;5:527-530.
61. Sweeney SM, Guy CA, Fields GB, San Antonio JD. Defining the domains of type I collagen involved in heparin-binding and endothelial tube formation. Proc Nat Acad Sci USA. 1998;95:7275-7280.
62. Maurice DM, Mishima S. Ocular pharmacokinetics. Ocul Pharmacol. Berlin: Springer-Verlag; 1984;69:20-107.
63. Yu H, Tyrell D, Cashel J, et al. Specificities of heparin-binding sites from the amino terminus and type I repeats of thrombospondin-1. Arch Biochem Biophys. 2000;374:13-23.
64. Sipes JM, Krutzsch HC, Lawler J, Roberts DD. Cooperation between thrombospondin-1 type I repeat peptides and alpha (v) beta (3) integrin ligands to promote melanoma spreading and focal adhesion kinase phosphorylation. J Biol Chem. 1999;274:22755-22762.
65. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
66. Idiom K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993;44:959-966.
67. Lute GA, Merges C, Threlkeld AB, Crone S, McLeod DS. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci. 1993;34:477-487.
68. Pascal LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23-30.
69. Sjostrand J, Karlsson JO, Andersson AK. Changes in the soluble protein of the human vitreous in vitreoretinal disease. Acta Ophthalmol. 1992;70:814-819.
70. Clausen R, Weller M, Wiedemann P, et al. An immunochemical quantitative analysis of the protein pattern in physiologic and pathologic vitreous. Graefes Arch Clin Exp Ophthalmol. 1991; 229:186-190.
71. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999;40:705-712.
72. Hirase K, Ikeda T, Sotozono C, et al. Transforming growth factor beta 2 in the vitreous of proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:738-741.
73. Suzuki K, Takagi H, Otani A, Oh H, Honda Y. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol. 1999;154:343-354.